1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Palonosetron + netupitant
Trade Name:
Akynzeo
Manufacturer/Distributor:
Purdue Pharma
Classification:
Antiemetic
ATC Class:
A04AA55 - palonosetron, combinations
Status:
active
Notice of Compliance (yyyy/mm/dd):
2017/09/28
Date Marketed in Canada (yyyy/mm/dd):
2017/12/04
Presentation:
Capsule: 0.5 mg palonosetron + 300 mg netupitant
Comments:
In combination with dexamethasone, is indicated for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy OR prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone.
Netuptitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors. Delayed emesis has been associated with activation of NK1 receptors by substance P. Palonosetron is a 5-HT3 receptor antagonist.
Back to:
Drug Product Listings 
